- Home
- FMC vs VKTX Comparison
FMC vs VKTX Comparison
Compare FMC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMC | VKTX |
|---|---|---|
| Founded | 1910 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.8B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | FMC | VKTX |
|---|---|---|
| Price | $13.25 | $38.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $25.83 | ★ $87.07 |
| AVG Volume (30 Days) | ★ 4.8M | 3.5M |
| Earning Date | 10-29-2025 | 10-22-2025 |
| Dividend Yield | ★ 17.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,608,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.17 | $18.92 |
| 52 Week High | $59.88 | $52.58 |
Technical Indicators
Market Signals| Indicator | FMC | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.37 | 59.93 |
| Support Level | $12.17 | $33.81 |
| Resistance Level | $14.50 | $36.68 |
| Average True Range (ATR) | 0.59 | 2.19 |
| MACD | 0.72 | -0.16 |
| Stochastic Oscillator | 47.21 | 82.16 |
Price Performance
Historical ComparisonAbout FMC FMC Corporation
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.